Okla. Admin. Code § 310:515-1-4

Current through Vol. 41, No. 19, June 17, 2024
Section 310:515-1-4 - Additional diseases, conditions, and injuries to be reported

The following diseases, conditions and injuries must be reported by physicians, laboratories, and hospitals (by infection control practitioners, medical records personnel, and other designees) to the OSDH as dictated in the following subsections:

(1)Infectious diseases. Reports of infectious diseases and conditions listed in this subsection must be submitted electronically via secure electronic data transmission to the OSDH within one (1) working day (Monday through Friday, state holidays excepted) of diagnosis or positive test.
(A) Acid Fast Bacillus (AFB) positive smear. Report only if no additional testing is performed or subsequent testing is indicative of Mycobacterium tuberculosis Complex.
(B) AIDS.
(C)Anaplasma phagocytophilum infection.
(D) Arboviral infections (West Nile virus, St. Louis encephalitis virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Powassan virus, California serogroup virus, chikungunya virus, Zika virus).
(E) Brucellosis (Brucella spp.).
(F) Campylobacteriosis (Campylobacter spp.).
(G) Congenital rubella syndrome.
(H) Cryptosporidiosis (Cryptosporidium spp.).
(I) Cyclosporiasis (Cyclospora cayetanensis).
(J) Dengue Fever.
(K)E. coli O157, O157:H7, or a Shiga toxin producing E. coli. (STEC)
(L) Ehrlichiosis (Ehrlichia spp.).
(M)Haemophilus influenzae invasive disease.
(N) Hantavirus infection, without pulmonary syndrome.
(O) Hantavirus pulmonary syndrome.
(P) Hemolytic uremic syndrome, postdiarrheal.
(Q) Hepatitis A infection (Anti-HAV-IgM+).
(R) Hepatitis B infection. If any of the following are positive, then all test results on the hepatitis panel must be reported: HBsAg+, anti-HBc-IgM+, HBeAg+, or HBV DNA+. For infants < or = 18 months, all hepatitis B related tests ordered, regardless of test result, must be reported.
(S) Hepatitis C infection in persons having jaundice or ALT > or = 200 with laboratory confirmation. If hepatitis C EIA is confirmed by NAT for HCV RNA, or s/co ratio or index is predictive of a true positive then report results of the entire hepatitis panel. For infants < or = 18 months, all hepatitis C related tests ordered, regardless of test result, must be reported. Positive HCV RNA are reportable by both laboratories and providers. Negative test results for HCV RNA tests are reportable by laboratories only.
(T) HIV.
(i) All tests indicative of HIV infection are reportable by laboratories and providers. If any HIV test is positive, then all HIV test results on the panel must be reported by laboratories. For infants < or = 18 months, all HIV tests ordered, regardless of test result must be reported.
(ii) All HIV nucleotide sequences and negative HIV test results are only reportable by laboratories.
(U) Influenza-associated hospitalization or death.
(V) Legionellosis (Legionella spp.)
(W) Leptospirosis (Leptospira interrogans).
(X) Listeriosis (Listeria monocytogenes).
(Y) Lyme disease (Borrelia burgdorferi).
(Z) Malaria (Plasmodium spp.).
(AA) Mumps.
(BB) Pertussis (Bordetella pertussis).
(CC) Psittacosis (Chlamydophila psittaci).
(DD) Q fever (Coxiella burnetii).
(EE) Rubella.
(FF) Salmonellosis (Salmonella spp.).
(GG) SARS-CoV-2 (COVID-19).
(HH) Shigellosis (Shigella spp.).
(II) Spotted Fever Rickettsiosis (Rickettsia spp.) hospitalization or death.
(JJ) Streptococcal disease, invasive, Group A (GAS) (Streptococcus pyogenes).
(KK)Streptococcus pneumoniae invasive disease, in persons less than 5 years of age.
(LL) Syphilis (Treponema pallidum). Nontreponemal and treponemal tests are reportable. If any syphilis test is positive, then all syphilis test results on the panel must be reported. For infants < or = 18 months, all syphilis tests ordered, regardless of test result, must be reported.
(MM) Tetanus (Clostridium tetani).
(NN) Trichinellosis (Trichinella spiralis).
(OO) Tuberculosis (Mycobacterium tuberculosis).
(PP) Tularemia (Francisella tularensis).
(QQ) Unusual disease syndrome.
(RR) Vibriosis (Vibrionaceae family: Vibrio spp. (including cholera), Grimontia spp. , Photobacterium spp.,and other genera in the family).
(SS) Yellow Fever.
(2)Infectious diseases. Reports of infectious diseases and conditions listed in this subsection must be reported to the OSDH via secure electronic data submission within one (1) month of diagnosis or test result.
(A) CD4 cell count with corresponding CD4 cell count percentage of total (by laboratories only).
(B) Chlamydia (Chlamydia trachomatis).
(C) Creutzfeldt-Jakob disease.
(D) Gonorrhea (Neisseria gonorrhoeae).
(E) HIV viral load (by laboratories only).
(F) LGV. Lymphogranuloma Venereum is reportable as Chlamydia and designated as LGV.
(3)Occupational or environmental diseases. Laboratories and healthcare providers must report blood lead level results pursuant to the requirements established in Title 310, Chapter 512, childhood Lead Poisoning Prevention Rules.
(4)Injuries.
(A) Burns.
(B) Drownings and near drownings.
(C) Traumatic brain injuries.
(D) Traumatic spinal cord injuries.
(E) Poisonings, including toxic and adverse effects.

Okla. Admin. Code § 310:515-1-4

Amended at 9 Ok Reg 485, eff 1-1-92 (emergency); Amended at 9 Ok Reg 1429, eff 5-1-92; Amended at 10 Ok Reg 1997, eff 6-1-93; Amended at 11 Ok Reg 3837, eff 7-11-94; Amended at 17 Ok Reg 2942, eff 7-13-00; Amended at 19 Ok Reg 1285, eff 5-28-02; Amended at 20 Ok Reg 2366, eff 7-11-03; Amended at 24 Ok Reg 1978, eff 6-25-07; Amended at 26 Ok Reg 2033, eff 6-25-09; Amended at 27 Ok Reg 2522, eff 7-25-10; Amended at 29 Ok Reg 1601, eff 7-12-12
Amended by Oklahoma Register, Volume 31, Issue 24, September 2, 2014, eff. 9/12/2014
Amended by Oklahoma Register, Volume 34, Issue 24, September 1, 2017, eff. 10/1/2017
Amended by Oklahoma Register, Volume 37, Issue 24, September 1, 2020, eff. 9/11/2020
Amended by Oklahoma Register, Volume 39, Issue 01, September 15, 2021, eff. 8/12/2021
Amended by Oklahoma Register, Volume 39, Issue 24, September 1, 2022, eff. 9/11/2022
Amended by Oklahoma Register, Volume 40, Issue 23, August 15, 2023, eff. 9/11/2023